Zydus Lifesciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.6 pts more than Nifty 100 and 1.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Zydus Lifesciences reported standalone revenue of ₹131,515 million for FY2026, down 17% from ₹158,125 million in FY2025. Net profit fell significantly to ₹35,598 million from ₹57,749 million, a decline of about 38%. On a consolidated basis, revenue grew 17% to ₹271,484 million driven by acquisitions including Amplitude Surgical SAS (added July 2025). The company recorded an exceptional item of ₹1,669 million due to impairment in Zydus VTEC Limited investment. Auditors Deloitte gave an unmodified (clean) opinion. The board recommended a final dividend of ₹1 per share (100% payout). PAT declined despite higher consolidated revenue, partly due to the impairment charge and lower other income.
The sharp decline in standalone profit despite consolidated revenue growth indicates margin pressure and one-time charges. Shareholders may see the dividend as a positive signal, but the profit decline and impairment charge are concerns.